Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Insider Lisa Bright Sells 142 Shares

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) insider Lisa Bright sold 142 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $110.29, for a total transaction of $15,661.18. Following the transaction, the insider now owns 23,477 shares in the company, valued at approximately $2,589,278.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lisa Bright also recently made the following trade(s):

  • On Monday, July 3rd, Lisa Bright sold 394 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $121.33, for a total transaction of $47,804.02.
  • On Thursday, June 1st, Lisa Bright sold 698 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $110.73, for a total transaction of $77,289.54.
  • On Thursday, May 25th, Lisa Bright sold 254 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $117.52, for a total transaction of $29,850.08.
  • On Tuesday, May 16th, Lisa Bright sold 113 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $119.74, for a total transaction of $13,530.62.

Shares of Intercept Pharmaceuticals, Inc. (ICPT) traded up 2.05% during trading on Friday, hitting $103.19. 343,264 shares of the stock were exchanged. The firm has a 50 day moving average price of $120.81 and a 200 day moving average price of $117.78. The firm’s market capitalization is $2.59 billion. Intercept Pharmaceuticals, Inc. has a 52 week low of $96.63 and a 52 week high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($3.14) EPS. Analysts forecast that Intercept Pharmaceuticals, Inc. will post ($14.05) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/intercept-pharmaceuticals-inc-nasdaqicpt-insider-lisa-bright-sells-142-shares-updated/1351149.html.

ICPT has been the topic of several research reports. Credit Suisse Group boosted their price objective on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a report on Monday, May 15th. ValuEngine raised shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research cut shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Finally, Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 10th. They issued a “buy” rating and a $275.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $203.67.

Hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. US Bancorp DE purchased a new position in shares of Intercept Pharmaceuticals during the first quarter worth about $130,000. IFP Advisors Inc increased its position in shares of Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 730 shares during the period. Quantbot Technologies LP purchased a new position in shares of Intercept Pharmaceuticals during the first quarter worth about $170,000. Finally, Pacer Advisors Inc. increased its position in shares of Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares during the period. Hedge funds and other institutional investors own 83.93% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies
Boston’s Chris Sale Will Pitch In Each of Three Series With Yankees
Boston’s Chris Sale Will Pitch In Each of Three Series With Yankees
Greg Holland Out For Rockies Following Kitchen Incident
Greg Holland Out For Rockies Following Kitchen Incident


Leave a Reply

 
© 2006-2017 BBNS.